Clinical Trial

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2025-04-03; most recent amendment 2026-05-12.
Status change: Not Yet Recruiting → Recruiting 2025-06-03
Trial Details
NCT Number NCT06922591
Lead Sponsor Tango Therapeutics, Inc.
Collaborators: Revolution Medicines, Inc.
Conditions PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer Metastatic, Thoracic Cancer
Enrollment 183 participants
Start Date 2025-05-31
Primary Completion 2027-06 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-14